M&A / Deals Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug BioPharma DiveIf consummated, the deal would hand Merck a treatment that could challenge Novartis fast-selling Scemblix.M&A / DealsHematologyRead full story pharminent March 25, 2026 (Last updated: March 25, 2026) BioPharma Dive If consummated, the deal would hand Merck a treatment that could challenge Novartis fast-selling Scemblix. M&A / DealsHematologyRead full story Post navigation Previous: Karyopharm myeloma drug yields mixed data in myelofibrosis trialNext: Sarepta sees early success with RNAi drugs from Arrowhead Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026